Open Label Study to Assess Long-term Safety of Repeat Administration of Botulinum Toxin Type A for Moderate to Severe Crow's Feet Lines

• Status: Terminated
• Trial end date: 2013-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the long-term safety of botulinum toxin type A for the treatment of moderate to severe crow's feet lines after repeat application.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Revance Therapeutics, Inc.
• Treatments: abobotulinumtoxinA; Botulinum Toxins; Botulinum Toxins, Type A; incobotulinumtoxinA; onabotulinumtoxinA

Criteria

Inclusion Criteria:

• Moderate to severe crow's feet lines

• Female or male, 18 years of age and above and in good general health

• Women of childbearing potential must agree to use an effective method of birth control during the course of the study

Exclusion Criteria:

• Any neurological condition that may place the subject at increased risk with exposure to botulinum toxin type A

• Muscle weakness or paralysis, particularly in the area receiving study treatment

• Active skin disease or irritation at the treatment area

• Deep dermal scarring, or inability to smooth out the crow's feet lines to be treated by manually spreading the skin apart

• Treatment with botulinum toxin type A for crow's feet lines in the last 3 months

• Chemical peel during the 9 months prior to treatment

• Use of prescription retinoid products during the 3 months prior to treatment